Analysts Anticipate CytomX Therapeutics Inc. (CTMX) to Post ($0.35) Earnings Per Share
CytomX Therapeutics Inc. (NASDAQ:CTMX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus price objective of $20.00 for the company and are predicting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given CytomX Therapeutics an industry rank of 105 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/analysts-anticipate-cytomx-therapeutics-inc-ctmx-to-post-0-35-earnings-per-share.html
Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up 1.31% during mid-day trading on Tuesday, hitting $13.14. The stock had a trading volume of 33,110 shares. The stock’s market cap is $476.82 million. The firm has a 50 day moving average price of $14.44 and a 200-day moving average price of $11.97. CytomX Therapeutics has a 12 month low of $9.01 and a 12 month high of $24.68.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. CytomX Therapeutics had a negative return on equity of 91.59% and a negative net margin of 579.42%. On average, equities research analysts forecast that CytomX Therapeutics will post ($1.59) EPS for the current year.
Hedge funds have recently modified their holdings of the company. Montecito Bank & Trust bought a new stake in shares of CytomX Therapeutics during the second quarter worth about $1,497,000. Schwab Charles Investment Management Inc. boosted its stake in shares of CytomX Therapeutics by 82.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 41,722 shares of the company’s stock worth $427,000 after buying an additional 18,794 shares during the period. Redmile Group LLC boosted its stake in shares of CytomX Therapeutics by 0.6% in the second quarter. Redmile Group LLC now owns 733,899 shares of the company’s stock worth $7,497,000 after buying an additional 4,200 shares during the period. Metropolitan Life Insurance Co. NY bought a new stake in shares of CytomX Therapeutics during the second quarter worth about $175,000. Finally, Opaleye Management Inc. bought a new stake in shares of CytomX Therapeutics during the second quarter worth about $1,634,000. 51.95% of the stock is currently owned by institutional investors and hedge funds.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.